Navigation

Roche banking on DNA diagnosis

Swiss drugmaker Roche has said it plans to offer shareholders $5.7 billion (SFr5.29 billion) for San Diego-based DNA diagnostics company Illumina.

This content was published on January 25, 2012 - 10:55
swissinfo.ch and agencies

Roche reckons the deal will accelerate routine clinical use of DNA testing. The Basel-based holding added that buying Illumina would strengthen Roche's position in diagnostics because the companies' technologies are complementary.

Roche's planned tender offer of $44.50 per share would represent an 18 per cent premium over Tuesday's closing price of $37.69 for Illumina shares.

Roche said the offer price is 64 per cent higher than the last closing price before speculation surfaced in December that Roche was considering acquiring the American firm.

Roche, which has more than 80,000 employees and specialises in cancer diagnosis and diabetes management, said it has tried to negotiate a deal, but Illumina has declined to participate.

If the buyout proceeds, Roche plans to move the headquarters for its applied science business to San Diego but maintain operations for the unit in Penzberg, Germany, where it's now based.

Illumina has told shareholders it would look at the offer before making any recommendations on whether to sell.

Articles in this story

This article was automatically imported from our old content management system. If you see any display errors, please let us know: community-feedback@swissinfo.ch

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

Share this story

Change your password

Do you really want to delete your profile?